Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences Inc. demonstrates a strong positive outlook due to the promising preclinical results of its allogeneic CAR-NK therapies, particularly SENTI-202, which has shown significant anti-tumor activity and improved survival in preclinical models, positioning the company favorably in the oncology market. The engineered NK cells' enhanced safety profile and multi-target capabilities provide a competitive edge over existing therapies, especially with increasing support from regulatory authorities through Orphan Drug Designation (ODD), which facilitates collaboration and accelerates development. Additionally, the focus on durability and the expectation of positive data updates in 4Q25 further bolster confidence in Senti Biosciences' potential to capture substantial market opportunities in an evolving landscape of cell and gene therapies.

Bears say

Senti Biosciences Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include the potential decline in the clinical complete response (cCR) rate for its lead therapy, SENTI-202, due to the aggressive nature of acute myeloid leukemia (AML), alongside broader concerns regarding safety signals and efficacy outcomes in clinical trials. Furthermore, the company's market capitalization of approximately $47 million is notably lower than that of its competitors, indicating a lack of investor confidence that may be exacerbated by anticipated financing needs and a limited cash runway extending into late 2025, raising concerns about the company’s future viability and competitive positioning in the biotechnology sector.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.